美国 · SEC FORM 4
aTYR PHARMA INC
ATYR · Nasdaq · CIK 0001339970 · Healthcare · Biotechnology
内部人信号
1 位买方 · 1 条买入交易行 · $50.0K 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
- ⚠ Purchase size is modest relative to the model scale
- ⚠ Purchase activity is becoming less recent
- ✓ 角色得分高 · 买入者中职位最高的是：Director
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 43.4
- 43.3
- 43.3
- 43.2
- 43.2
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -43.0%
- 3M
- -51.2%
- 6M
- -70.4%
- 12M
- -75.4%
波动率与流动性
- 波动率
- 115.5%
- Beta
- —
- 平均每日成交额
- USD 805,673
估值
- 市值
- USD 24.1M
- P/E
- —
基本面
- 利润率
- —
- ROE
- -109.8%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-09 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-07-31 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 12,893,008
- 上期报告
- 10,668,157
- 日均成交量
- 13,422,383
- 回补天数
- ≤ 1.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-05-27 | SCHIMMEL PAUL | 买入 (P) | Common Stock | 100,000 | USD 0.50 | USD 50,000 | SEC 申报 ↗ |
| 2025-10-09 | SCHIMMEL PAUL | 买入 (P) | Common Stock | 317,999 | USD 0.94 | USD 298,919 | SEC 申报 ↗ |
| 2025-10-08 | SCHIMMEL PAUL | 买入 (P) | Common Stock | 682,001 | USD 0.90 | USD 613,801 | SEC 申报 ↗ |
| 2025-03-17 | Gross Jane A | 买入 (P) | Common Stock | 3,750 | USD 4.00 | USD 15,000 | SEC 申报 ↗ |
| 2024-07-24 | SCHIMMEL PAUL | 买入 (P) | Common Stock | 52,300 | USD 1.93 | USD 100,939 | SEC 申报 ↗ |
| 2024-07-23 | SCHIMMEL PAUL | 买入 (P) | Common Stock | 6,648 | USD 1.82 | USD 12,099 | SEC 申报 ↗ |
| 2024-07-22 | SCHIMMEL PAUL | 买入 (P) | Common Stock | 41,052 | USD 1.74 | USD 71,430 | SEC 申报 ↗ |
| 2024-06-05 | DENYES NANCY | 买入 (P) | Common Stock | 5,000 | USD 1.86 | USD 9,300 | SEC 申报 ↗ |
| 2024-05-31 | Shukla Sanjay | 买入 (P) | Common Stock | 20,000 | USD 1.81 | USD 36,200 | SEC 申报 ↗ |
| 2024-05-31 | Broadfoot Jill Marie | 买入 (P) | Common Stock | 5,000 | USD 1.79 | USD 8,950 | SEC 申报 ↗ |
| 2024-05-30 | COUGHLIN TIMOTHY | 买入 (P) | Common Stock | 50,000 | USD 1.75 | USD 87,500 | SEC 申报 ↗ |
| 2023-12-12 | Shukla Sanjay | 买入 (P) | Common Stock | 12,000 | USD 1.18 | USD 14,160 | SEC 申报 ↗ |
| 2023-12-11 | Shukla Sanjay | 买入 (P) | Common Stock | 3,000 | USD 1.17 | USD 3,510 | SEC 申报 ↗ |
| 2023-11-13 | Shukla Sanjay | 买入 (P) | Common Stock | 13,578 | USD 1.11 | USD 15,072 | SEC 申报 ↗ |
| 2023-11-10 | Shukla Sanjay | 买入 (P) | Common Stock | 1,422 | USD 1.14 | USD 1,621 | SEC 申报 ↗ |
Form 4 申报证据
7 transaction lines in the latest 365-day window; 71 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-05-27 | SCHIMMEL PAUL | 买入 (P) | Common Stock | 100,000 | USD 0.50 | USD 50,000 | SEC 申报 ↗ |
| 2026-02-04 | Shukla Sanjay | 卖出 (S) | Common Stock | 3,745 | USD 0.98 | USD 3,670 | SEC 申报 ↗ |
| 2026-02-04 | DENYES NANCY | 卖出 (S) | Common Stock | 1,118 | USD 0.98 | USD 1,096 | SEC 申报 ↗ |
展开近期 Form 4 证据 (7 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-05-27 | SCHIMMEL PAUL | 买入 (P) | Common Stock | 100,000 | USD 0.50 | USD 50,000 | SEC 申报 ↗ |
| 2026-02-04 | Shukla Sanjay | 卖出 (S) | Common Stock | 3,745 | USD 0.98 | USD 3,670 | SEC 申报 ↗ |
| 2026-02-04 | DENYES NANCY | 卖出 (S) | Common Stock | 1,118 | USD 0.98 | USD 1,096 | SEC 申报 ↗ |
| 2026-02-04 | Broadfoot Jill Marie | 卖出 (S) | Common Stock | 1,558 | USD 0.98 | USD 1,527 | SEC 申报 ↗ |
| 2026-02-03 | Shukla Sanjay | 期权行权／转换 (M) | Common Stock | 10,375 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-03 | DENYES NANCY | 期权行权／转换 (M) | Common Stock | 2,687 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-03 | Broadfoot Jill Marie | 期权行权／转换 (M) | Common Stock | 3,750 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ATYR |
| CIK | 0001339970 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 71 transaction lines from 2020-02-06 to 2026-05-27 28 P purchase lines · 18 S sale lines · 25 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.